(Q63399090)

English

HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

clinical trial

In more languages

default for all languages

No label defined

No description defined

edit

Statements

instance of

clinical trial

0 references

title

Phase 1 Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for HER2 Positive Recurrent/Refractory Pediatric Central Nervous System Tumors (English)

0 references

0 references

0 references

0 references

United States of America

0 references

start time

26 July 2018

0 references

end time

26 July 2021

0 references

number of participants

36

0 references

clinical trial phase

phase I clinical trial

0 references

maximum age

26 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT03500991

0 references

(Q63399090)

HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)